Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis

Eugenia Raichlin, Abhiram Prasad, Verghese Mathew, Bailey Kent, David R. Holmes, Geralyn M. Pumper, Rebecca E. Nelson, Lilach O. Lerman, Amir Lerman

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92±10 to 80±10 mm Hg (P<0.001) in the atrasentan group and did not change in the placebo group (93±10 and 92±11 mm Hg; P=0.84). The difference between the groups was significant (P<0.001). No effect on heart rate was observed. In a subgroup of patients not treated with angiotensin-converting enzyme inhibitor, creatinine level decreased in the atrasentan versus the placebo group (P=0.011). Fasting glucose (P=0.026), glycosylated hemoglobin level (P=0.041), triglyceride l (P=0.013), lipoprotein-A (P=0.046), and uric acid levels (P=0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)522-528
Number of pages7
JournalHypertension
Volume52
Issue number3
DOIs
StatePublished - Sep 1 2008

Fingerprint

Atherosclerosis
Safety
Placebos
Arterial Pressure
Glucose
atrasentan
Endothelins
Glycosylated Hemoglobin A
Uric Acid
Lipid Metabolism
Nose
Angiotensin-Converting Enzyme Inhibitors
Lipoproteins
Coronary Disease
Headache
Coronary Artery Disease
Fasting
Edema
Creatinine
Angiography

Keywords

  • Blood pressure
  • Edema
  • Endothelin
  • Endothelin-A receptor
  • Hypertension
  • Metabolic syndrome

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Raichlin, E., Prasad, A., Mathew, V., Kent, B., Holmes, D. R., Pumper, G. M., ... Lerman, A. (2008). Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension, 52(3), 522-528. https://doi.org/10.1161/HYPERTENSIONAHA.108.113068

Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. / Raichlin, Eugenia; Prasad, Abhiram; Mathew, Verghese; Kent, Bailey; Holmes, David R.; Pumper, Geralyn M.; Nelson, Rebecca E.; Lerman, Lilach O.; Lerman, Amir.

In: Hypertension, Vol. 52, No. 3, 01.09.2008, p. 522-528.

Research output: Contribution to journalArticle

Raichlin, E, Prasad, A, Mathew, V, Kent, B, Holmes, DR, Pumper, GM, Nelson, RE, Lerman, LO & Lerman, A 2008, 'Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis', Hypertension, vol. 52, no. 3, pp. 522-528. https://doi.org/10.1161/HYPERTENSIONAHA.108.113068
Raichlin, Eugenia ; Prasad, Abhiram ; Mathew, Verghese ; Kent, Bailey ; Holmes, David R. ; Pumper, Geralyn M. ; Nelson, Rebecca E. ; Lerman, Lilach O. ; Lerman, Amir. / Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. In: Hypertension. 2008 ; Vol. 52, No. 3. pp. 522-528.
@article{3b1a7529b13947499b9de696bfd83134,
title = "Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis",
abstract = "Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92±10 to 80±10 mm Hg (P<0.001) in the atrasentan group and did not change in the placebo group (93±10 and 92±11 mm Hg; P=0.84). The difference between the groups was significant (P<0.001). No effect on heart rate was observed. In a subgroup of patients not treated with angiotensin-converting enzyme inhibitor, creatinine level decreased in the atrasentan versus the placebo group (P=0.011). Fasting glucose (P=0.026), glycosylated hemoglobin level (P=0.041), triglyceride l (P=0.013), lipoprotein-A (P=0.046), and uric acid levels (P=0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome.",
keywords = "Blood pressure, Edema, Endothelin, Endothelin-A receptor, Hypertension, Metabolic syndrome",
author = "Eugenia Raichlin and Abhiram Prasad and Verghese Mathew and Bailey Kent and Holmes, {David R.} and Pumper, {Geralyn M.} and Nelson, {Rebecca E.} and Lerman, {Lilach O.} and Amir Lerman",
year = "2008",
month = "9",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.108.113068",
language = "English (US)",
volume = "52",
pages = "522--528",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis

AU - Raichlin, Eugenia

AU - Prasad, Abhiram

AU - Mathew, Verghese

AU - Kent, Bailey

AU - Holmes, David R.

AU - Pumper, Geralyn M.

AU - Nelson, Rebecca E.

AU - Lerman, Lilach O.

AU - Lerman, Amir

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92±10 to 80±10 mm Hg (P<0.001) in the atrasentan group and did not change in the placebo group (93±10 and 92±11 mm Hg; P=0.84). The difference between the groups was significant (P<0.001). No effect on heart rate was observed. In a subgroup of patients not treated with angiotensin-converting enzyme inhibitor, creatinine level decreased in the atrasentan versus the placebo group (P=0.011). Fasting glucose (P=0.026), glycosylated hemoglobin level (P=0.041), triglyceride l (P=0.013), lipoprotein-A (P=0.046), and uric acid levels (P=0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome.

AB - Endothelin plays an important role in the pathogenesis of atherosclerosis. The aim of the study was to evaluate the safety and hemodynamic and metabolic responses to 6 months treatment with atrasentan, the selective endothelin-A receptor antagonist. Seventy-two patients with multiple cardiovascular risk factors and nonobstructive coronary artery disease on coronary angiogram were randomly assigned in a double-blind manner to atrasentan or placebo. Mean aortic blood pressure decreased from 92±10 to 80±10 mm Hg (P<0.001) in the atrasentan group and did not change in the placebo group (93±10 and 92±11 mm Hg; P=0.84). The difference between the groups was significant (P<0.001). No effect on heart rate was observed. In a subgroup of patients not treated with angiotensin-converting enzyme inhibitor, creatinine level decreased in the atrasentan versus the placebo group (P=0.011). Fasting glucose (P=0.026), glycosylated hemoglobin level (P=0.041), triglyceride l (P=0.013), lipoprotein-A (P=0.046), and uric acid levels (P=0.048) decreased significantly in the atrasentan group compared with the placebo group. No progression of angiographic coronary disease was observed. The most common adverse effects with atrasentan were nasal stuffiness, headache, and edema. In conclusion, 6 months of treatment with atrasentan results in a reduction of blood pressure and improvement in glucose and lipid metabolism. These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome.

KW - Blood pressure

KW - Edema

KW - Endothelin

KW - Endothelin-A receptor

KW - Hypertension

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=52049097771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049097771&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.108.113068

DO - 10.1161/HYPERTENSIONAHA.108.113068

M3 - Article

VL - 52

SP - 522

EP - 528

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -